Home    Back

299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2008-001156-43-PT
(EUCTR)		23/06/200905/05/2009A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis.A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis. Cystic fibrosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis		Trade Name: Spiriva Respimat 2.5 microgram, solution for inhalation
INN or Proposed INN: Tiotropium
Product Name: Tiotropium Respimat 1.25 microgram solution for inhalation
INN or Proposed INN: Tiotropium		Boehringer Ingelheim Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes		596Portugal;United Kingdom;Germany;Netherlands;Belgium;France;Italy
2EUCTR2008-001156-43-NL
(EUCTR)		15/01/200915/09/2008A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis. - Tiotropium in CFA randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis. - Tiotropium in CF Cystic fibrosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis		Trade Name: Spiriva Respimat 2.5 microgram, solution for inhalation
Other descriptive name: TIOTROPIUM
Product Name: Tiotropium Respimat 1.25 microgram solution for inhalation
Other descriptive name: TIOTROPIUM		Boehringer Ingelheim bvNULLNot RecruitingFemale: yes
Male: yes		596Portugal;United Kingdom;Germany;Netherlands;Belgium;France;Italy
3EUCTR2008-001156-43-FR
(EUCTR)		19/09/200813/06/2008A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis.A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis. Cystic fibrosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis		Trade Name: Spiriva Respimat 2.5 microgram, solution for inhalation
Other descriptive name: TIOTROPIUM
Product Name: Tiotropium Respimat 1.25 microgram solution for inhalation
Other descriptive name: TIOTROPIUM		Boehringer Ingelheim FranceNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		596Portugal;United Kingdom;Germany;Netherlands;Belgium;France;Italy
4EUCTR2008-001156-43-GB
(EUCTR)		11/09/200814/10/2008A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis.A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis. Cystic fibrosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis		Trade Name: Spiriva Respimat 2.5 microgram, solution for inhalation
Other descriptive name: TIOTROPIUM
Product Name: Tiotropium Respimat 1.25 microgram solution for inhalation
Other descriptive name: TIOTROPIUM		Boehringer Ingelheim LimitedNULLNot RecruitingFemale: yes
Male: yes		596Portugal;Germany;United Kingdom;Netherlands;Belgium;France;Italy
5EUCTR2008-001156-43-BE
(EUCTR)		22/07/200816/06/2008A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis.A randomized, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat device for 12 weeks in patients with cystic fibrosis. Cystic fibrosis.
MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis		Trade Name: Spiriva Respimat 2.5 microgram, solution for inhalation
Other descriptive name: TIOTROPIUM
Product Name: Tiotropium Respimat 1.25 microgram solution for inhalation
Other descriptive name: TIOTROPIUM		SCS Boehringer Ingelheim Comm.VNULLNot RecruitingFemale: yes
Male: yes		596Portugal;United Kingdom;Germany;Netherlands;Belgium;France;Italy

Back to top